·         Home

·         Research Interests

·         Group Members

·         Publications


Tumour Growth Control Group (CRUK) - Sir William Dunn School of Pathology


Buehnemann, C., Li, S., Brandford-White, H., Yu, H., Hogendoorn, P.C., Llombart-Bosch, A., Picci, P., Noble, A., Hassan, A.B.  Quantification of the heterogeneity of prognostic cellular biomarkers in Ewing Sarcoma using automated image and random survival forest analysis. (2014) PlosOne Sep 2014 9 (9) e107105.



Hughes, J., Frago, S., Bühnemann, C., Carter, E.J. and Hassan, A.B. Maternal transmission of a humanised Igf2r allele results in an Igf2 dependent  hypomorphic and non-viable growth phenotype. (2013) PlosOne e57270.

Barnes, D.J., Mumtaz, M., Hughes, J., Buehnemann, C., Hoppe, H., Zhang, S., Prince, S.N., Taylor, S. and Hassan, A.B.  IGF2 signalling regulates the transcription module of the repressor REST in a specific and gene dosage dependent manner in genetic models of ligand supply. (2013) in preparation.

Frago, S., Strickland, M., Hughes,J., Williams,C., Garner, L., Hoppe,H-J., Rezgui, D., Zaccheo,O.J., Prince,S.N, Crump,M.P. and Hassan, A.B.  Directed evolution of structurally selected IGF2R domain 11 binding loop residues generates an IGF2 super-antagonist. (2013) in preparation.

Matheson, J., Bühnemann, C., Carter, E.J., Hughes, J., Hoppe, H-J., Hassan, A.B. Conditional disruption of Cdh1 (E-cadherin) modifies Apc loss of function in intestinal adenoma to promote cell death and mesenchymal transition. (2013) in preparation. 



Williams, C., Hoppe, H., Rezgui, D., Strickland, M., Frago, S., Forbes, B., Gutzner, F., Ellis, R.Z., Wattana-Amorn, P., Prince, S.N., Zaccheo, O.J., Jones, E.Y., Crump, M.C. and Hassan, A.B. An exon splice enhancer primes IGF2:IGF2R binding site for structure and functional evolution.  (2012) Science 338; 1209-13.

van Maldegem, A.M., Bhosale, A, Gelderblom, H.J, Hogendoorn, P.C., Hassan, A.B. Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment. Clin Sarcoma Res. (2012) Jan 27;2(1):5.

van Maldegem, A.M., Hogendoorn, P.C., Hassan, A.B.  The clinical use of biomarkers as prognostic factors in Ewing sarcoma. Clin Sarcoma Res. (2012) Feb 8;2(1):7.



Li, P., Cavallero, S., Gu, Y., Chen, T.H., Hughes, J., Hassan, A.B., Brüning, J.C., Pashmforoush, M., Sucov, H.M.  IGF signaling directs ventricular cardiomyocyte proliferation during embryonic heart development. (2011) Development. 138:1795-805.

Church, D., Carter, E., Phillips, B., Stuckey, D., Buffa, F., Manek, S., Clarke, K., Harris, A.L., Hassan, A.B.  Igf2 dependency of Pten (+/-) developmental and tumour phenotypes in the mouse. (2011) Oncogene, 31: 3635-46.

Haley, V.L., Barnes, D.J., Graham, C.F., Sandovici, I., Constancia, M. and Hassan, A.B. Synergistic and dependent genetic interactions between Igf2 and p53 during embryonic and tumour development, (2011) EMBO Molecular Medicine 4: 705-18.



Jeyaratnaganthan N., Hojlund, K., Kroustrup, J.P., Larsen, J.F., Bjerre, M., Levin, K., Beck-Nielson, H., Frago, S., Hassan, A.B., Flyvbjerg, A., Frystyk, J.  Circulating levels of insulin-like growth factor II/ Mannose-6-phosphate receptor in obesity and type 2 diabetes.  Growth Horm IGF Res. (2010) 20(3):185-91.

Casali, P.G., Blay, J.Y.; ESMO/ CONTICANET/ EUROBONET Consensus Panel of experts. Hassan, A.B. and 43 others.  Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up.  (2010) Annals of Oncology 21;Suppl 5:v98-102.

Hogendoorn, P.C.; ESMO/EuroBoNeT working Group, Athanasou, N., Bielack, S., De Alava, E., Tos, A.P., Ferrari, S., Gelderblom, H., Grimer, R., Hall, K.S., Hassan, A.B., Hogendoorn, P.C., Jurgens, H., Paulussen, M., Rozeman, L., Taminiau, A.H., Whelan, J., Vanel, D.  Bone Sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up.  (2010) Annals of Oncology 21; Suppl 5:v204-13.

Casali, P.G., Blay, J.Y.; ESMO/ CONTICANET/ EUROBONET Consensus Panel of experts. Hassan, A.B. and 43 others.  Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) Annals of Oncology 21;Suppl 5:v198-203.



Rezgui, D., Williams, C., Savage, S.A., Prince, S.N., Zaccheo, O.J., Jones, E.Y., Crump, M.P. and Hassan, A.B. Structure and function of the human Gly1619Arg polymorphism of M6P/IGF2R domain 11 implicated in IGF2 dependent growth. J Mol Endocrinology, (2009) 42:341-56.



Brown, J., Delaine, C., Zaccheo, O., Siebold, C., Gilbert, R., van Boxel, G., Denley, A., Wallace, J., Hassan, A.B., Forbes, B., and Jones E.Y. Structure and functional analysis of the IGF-II/IGF2R interaction. (2008) EMBO J 27:265-76.

Varey, A.H., Rennel, E.S., Qiu, Y., Bevan, H.S., Perrin, R.M., Raffy, S., Dixon, A.R., Paraskeva, C., Zaccheo, O., Hassan, A.B., Harper, S.J., Bates, D.O. VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer. (2008), 98, 1366-79.

Stocken, D.D., Hassan, A.B., Altman, D. et al.  Modelling prognostic factors in advanced pancreatic cancer.  Br J Cancer (2008). 99, 883-93.